Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1066 results about "Cell free" patented technology

Source of origin deconvolution based on methylation fragments in cell-free DNA samples

A method and system for determining one or more sources of a cell free deoxyribonucleic acid (cfDNA) test sample from a test subject. The cfDNA test sample contains a plurality of deoxyribonucleic acid (DNA) molecules with numerous CpG sites that may be methylated or unmethylated. A trained deconvolution model comprises a plurality of methylation parameters, including a methylation level at each CpG site for each source, and a function relating a sample vector as input and a source of origin prediction as output. The method generates a test sample vector comprising a site methylation metric relating to DNA molecules from the test sample that are methylated at that CpG site. The method inputs the test sample vector into the trained deconvolution model to generate a source of origin prediction indicating a predicted DNA molecule contribution of each source.
Owner:GRAIL INC

Cancer detection and classification using methylome analysis

There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.
Owner:UNIV HEALTH NETWORK +1

Cancer detection and classification using methylome analysis

This is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.
Owner:UNIV HEALTH NETWORK

An in vitro cell-free protein synthesis system (D2P system), its reagent kit and its applications

This invention provides an in vitro cell-free protein synthesis system, its reagent kit, and its applications, belonging to the field of protein synthesis technology. This invention improves an in vitro cell-free protein synthesis system based on Kluyveromyces lactis by adding exogenous L-arabinose, significantly enhancing the system's protein synthesis capacity. Furthermore, it provides a more efficient and higher-throughput in vitro protein synthesis reagent kit and a method for synthesizing exogenous proteins. The improvements provided by this invention can be achieved without molecular modification, are simple and convenient to operate, and save costs.
Owner:KANGMA (SHANGHAI) BIOTECH LTD

Precoding tracking for cell free massive MIMO

A method may include transmitting, by a network node within a wireless network to a reference node, a first precoded tracking signal based on estimated precoding weights that are estimated to provide a predetermined signal at the reference node; receiving, by the network node from the reference node, a message including information related to whether or not the predetermined signal was received at the reference node based, at least in part, on the first precoded tracking signal transmitted by the network node; performing the following, by the network node, if the predetermined signal was not received at the reference node: adjusting one or more transmission parameters of the network node, that is estimated to more accurately provide the predetermined signal at the reference node; and transmitting, by the network node, a second precoded tracking signal based on adjusted transmission parameters.
Owner:NOKIA TECHNOLOGIES OY

Protein expression reagents

Provided herein are methods of cell-free protein synthesis, optimised cell-free protein synthesis (CFPS) reagents for the expression of eukaryotic proteins and methods for optimising CFPS reagents to increase protein expression yields for mammalian proteins and subsequent expression in cells. The methods are applicable to protein expression on a microfluidic device having hydrophobic surfaces by merging droplets on the device in order to screen a selection of expression compositions in parallel and then identify the optimum conditions for producing the stable folded protein in a cell-based system.
Owner:NUCLERA LTD

Methods and systems for generating sequencing libraries

Methods and systems for targeted detection of circulating tumor DNA (ctDNA) molecules are disclosed herein. In some cases, a molecular sequencing library depleted of methylated DNA can be generated and used to detect ctDNA in a cell-free DNA sample reliably at a lower sequencing depth and lower cost than existing methods.
Owner:ADELA INC

Virus DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) co-extraction kit and extraction method

The invention relates to a virus DNA and RNA co-extraction kit and an extraction method, and belongs to the technical field of biology. By matching the lysate, the rinsing liquid and other solutions with the extraction method, the method can directly extract viral nucleic acids (DNA and RNA) in cell-free body fluids of human and animals, such as centrifugal supernatant of serum, plasma and tissue grinding fluid. According to the method and the kit, DNA and RNA can be extracted at the same time, operation is easy, particularly, the nucleic acid extraction sensitivity of the small viruses is high, and the extraction effect is better.
Owner:TIANJIN MOGENETICS BIOTECH CO LTD

Genetically engineered Vibrio sp. and uses thereof

ActiveUS12331326B2BacteriaTransferasesCell freeShuttle vector
The present disclosure relates to the seminal discovery of a generation and use of genetically engineered Vibrio sp. Provided is the use of the genetically engineered bacteria for the construction, maintenance, manipulation, and / or propagation of DNA constructs; protein expression; protein secretion; vectors and other metabolic tools; metabolic engineering; expression of cellular extracts for cell-free biology; shuttle vectors; cloning vectors; and for synthetic biology applications. The disclosure also relates to the use of the replication machinery of Vibrio sp. as a cloning or expression vector for replication of recombinant DNA constructs. The disclosure also relates to methods of use of the above.
Owner:TELESIS BIO INC

Methods for assaying circulating tumor DNA

The present disclosure includes a method of comprising (a) obtaining cell-free DNA (cfDNA) from a sample from a subject; (b) selectively enriching subsets of the cfDNA from (a) or derivatives therefrom having one or more target regions to obtain enriched DNA, wherein the target regions are differentially methylated in cancer; (c) sequencing the enriched DNA from (b) to obtain sequence reads; and (d) partitioning a plurality of the sequence reads into two or more groups based on their methylation status and determining the fragment length distribution of the sequence reads in at least one of the groups.
Owner:NATERA INC

Optimizing immunosuppression in transplant patients using personalized phenotypic dosing model

The art does not provide systematic and reproducible methods to personalize dosing of multiple immunosuppressive medications after transplantation. This invention provides a method to systematize multi-drug immuno suppression management in tissue and organ transplantation using an artificial intelligence-based complex systems approach. In embodiments of this invention, immunosuppression drug dose, blood drug concentrations, donor-derived fraction of cell free DNA (dd-cfDNA %), and aspartate aminotransferase are used to indicate allograft status or a proxy for allograft status, to generate a phenotypic response surface to produce individual treatment modalities and dosages using empirically determined unique coefficients. This surface is used to calculate appropriate immunosuppression drug doses associated with the desired outcome for that patient. Embodiments of this disclosure are directed to identifying optimized combinations of inputs for the complex system of the immunosuppressed transplant patient in order to avoid transplant rejection while avoiding unnecessary toxicity and maintaining a robust enough immune response to fight infection.
Owner:RGT UNIV OF CALIFORNIA +1

High-purity recombinant collagen as well as preparation method and application thereof

The invention discloses high-purity recombinant collagen as well as a preparation method and application thereof, the recombinant collagen is composed of a recombinant collagen monomer, and the recombinant collagen monomer has an amino acid sequence as shown in any one of SEQ ID NO: 1-22. According to the present invention, the easy-to-break site and the hydrophobicity of the collagen are optimized, such that the obtained recombinant collagen monomer and the prepared recombinant collagen have characteristics of high cell activity (adhesion, migration and proliferation), high triple helix structure stability, high purity, no cytotoxicity, large-scale production, and production cost reduction.
Owner:SHENZHEN KEXING MEDICAL EQUIPMENT CO LTD

ELISA kit for detecting anti-MDA5 antibody and preparation method thereof

The invention provides an ELISA (Enzyme Linked Immunosorbent Assay) kit for detecting an anti-MDA5 antibody and a preparation method of the ELISA kit. According to the kit, full-length human MDA5 protein (1025 amino acids) expressed by a cell-free protein expression system under the low-temperature condition of 22 DEG C is adopted as a coating antigen, and a disulfide bond enhancer E6820 is added into the system to promote correct folding of the protein. The kit comprises a microwell plate coated with a full-length MDA5 antigen, an enzyme-labeled anti-human IgG secondary antibody, a standard substance with the concentration range of 1-243 ng / mL, a chromogenic substrate and an optimized confining liquid system. The invention solves the problem of insufficient sensitivity caused by the use of fragment antigens in the prior art, and can be used for early diagnosis and illness monitoring of dermatomyositis-related interstitial lung diseases.
Owner:MUEN (WUHAN) MEDICAL & BIOTECHNOLOGY CO LTD

In vitro cell-free protein synthesis system and kit containing exogenous magnesium ions and applications thereof

The application provides an in-vitro cell-free protein synthesis system and kit containing exogenous magnesium ions and application thereof, including a D2P system (DNA-to-Protein system) and an mR2P system (mRNA-to-Protein system), and belongs to the technical field of protein synthesis. The in-vitro cell-free protein synthesis system containing exogenous magnesium ions adopts magnesium aspartate as a novel magnesium ion source, and especially in a eukaryotic cell-free system, compared with a traditional magnesium ion source, can significantly improve the protein synthesis efficiency and protein expression amount. A more efficient and higher-throughput in-vitro protein synthesis kit and a synthesis method of exogenous proteins are also provided, and the kit has the advantages of simplicity, convenience and low cost.
Owner:KANGMA (SHANGHAI) BIOTECH LTD

Amniotic Membrane Hydrogel and Methods of Making

The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta. In certain embodiments, the composition comprises amniotic membrane powder or solubilized amniotic membrane (SAM). In some aspects, the composition is cell-free and rich in cytokines, extracellular matrix proteins, and other components that improve tissue regeneration. In one aspect, the composition is a hydrogel scaffold that comprises amniotic membrane. The present invention reduces contraction and improves blood vessel development in regenerating tissue.
Owner:WAKE FOREST UNIVERSITY HEALTH SCIENCES INC

Antimicrobial peptide SETIT, encoding DNA and expression system

The present invention discloses an antimicrobial peptide SETIT, which is derived from Paspalum vaginatum and has an amino acid sequence as shown in SEQ ID NO: 1. Also disclosed are its encoding DNA and expression system. The antimicrobial peptide SETIT of the present invention has an obvious inhibitory effect on Gram-positive, Gram-negative bacteria and fungi, has high antibacterial efficiency and good broad-spectrum. By expressing the antimicrobial peptide SETIT using an edible Kluyveromyces marxianus cell-free expression system, an edible millet antimicrobial peptide can be obtained.
Owner:TIDETRON BIOWORKS TECH (GUANGZHOU) CO LTD

Methods and compositions for rapid detection and analysis of RNA and DNA cytosine methylation

Aspects of the present disclosure are directed to methods, compositions, and kits for detection and analysis of DNA and RNA cytosine methylation. Certain aspects include methods, compositions and kits useful in bisulfite sequencing of methylated nucleic acids, including methylated nucleic acids from low-input samples such as cell-free DNA and cell-free RNA. Also disclosed are methods and compositions for detection and quantification of 5-hydroxymethylcytosine in DNA.
Owner:UNIVERSITY OF CHICAGO

Systems and methods for performing clustering updates in cell-free networks

PCT designated stage expiredWO2025034497A1Site diversityTransmission monitoringRadio equipmentCell free
Systems and methods for clustering in cell-free networks are described herein. A cluster of one or more base stations provides radio access network (RAN) functionality to a user equipment (UE) within the wireless communication system in a cell-free manner (e.g., without using a base-station-centric cell context, as in prior wireless communication systems). A cluster that is serving a UE comprises one or more connected base stations (cBSs) that actively serve the UE. A clustering control function (CCF) of the network establishes and maintains the cluster that is serving one or more UEs. Herein, messaging systems and messaging types used by the CCF, base station(s), and UE(s) within this cell-free context are discussed. Initial clustering methods used by a CCF to form a cluster for a UE are discussed. Further, clustering update methods used by a CCF to maintain / modify a cluster for a UE are discussed.
Owner:APPLE INC

Method for highly sensitive DNA methylation analysis

Methods, compositions and kits are provided to amplify an amount of genomic methylated DNA that can be subsequently analyzed and / or sequenced. It has particular use with small amounts of DNA, including, but not limited to cell free DNA samples. In some embodiments, the ratio of polymerase and methyltransferase is controlled in order to provide maximum yields. In some embodiments, a dual primase / polymerase is used.
Owner:UNIVERSITY OF CHICAGO

Acellular regenerative products and methods of their manufacture

An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease.
Owner:LUCINA PATENT HOLDCO LLC

Gas exchange during electrowetting operations

Provided herein are methods for replenishing dissolved gas to aqueous droplets on a digital microfluidic device. Provided herein are methods of cell-free protein synthesis, optimized cell-free protein synthesis (CFPS) reagents, and methods for optimizing CFPS reagents to increase protein expression yield. The method is suitable for protein expression on microfluidic devices having hydrophobic surfaces by circulating a fill fluid to introduce additional oxygen.
Owner:NUCLERA LTD

Methods, kits and systems for determining the status of lung cancer and methods for treating lung cancer based on same

PCT designated stage expiredWO2025081121A1Microbiological testing/measurementDNA methylationCell free
The present disclosure includes, among other things, methods, kits, and systems for determining the status of lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that that are characteristic of the status of lung cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with lung cancer. In various embodiments a determined status is useful, e.g., in selecting treatment for and / or treating a lung cancer.
Owner:PRECEDE BIOSCIENCES INC +1

Method for improving low-temperature degradation efficiency of corn straw

A method for improving degradation efficiency of corn straw at low temperature comprises the steps that cell-free culture fluid PfCFs prepared from Pseudomonas fragi D12 participates in fermentation and degradation of the corn straw, the classification name of the strain D12 is Pseudomonas fragi D12, the strain D12 is preserved in China Center for Type Culture Collection, the preservation address is No. 299, 8th road, Wuchang District, Wuhan City, Hubei Province, China, and the preservation number is CGMCC NO. The preservation number is CCTCC (China Center For Type Culture Collection) NO: M2025126, and the preservation date is January 14, 2025. The acellular culture solution of the pseudomonas rubrassicae D12 can promote the growth of various normal-temperature bacteria and fungi functional bacteria at low temperature and improve the cold resistance of the functional bacteria, and CFS of the pseudomonas rubrassicae D12 also contains related enzymes capable of degrading lignin; at a low temperature, the PfCFs synchronously promotes the co-growth of bacteria bacillus subtilis and fungi Irpex lacteus, so that the degradation efficiency of the functional bacteria on lignocellulose in the corn straws is improved.
Owner:NORTHEAST INST OF GEOGRAPHY & AGRIECOLOGY C A S

Methods, kits and systems for determining the her2 status of cancer and methods for treating cancer based on same

PCT designated stage expiredWO2025081100A1Microbiological testing/measurementDNA methylationCell free
The present disclosure includes, among other things, methods, kits, and systems for determining HER2 status of cancer, e.g., a breast, gastric / gastroesophageal, colorectal, or lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that that are characteristic of HER2 status of cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with cancer. In various embodiments a determined HER2 status is useful, e.g., in selecting treatment for and / or treating a cancer, e.g., a breast, gastric / gastroesophageal, colorectal, or lung cancer.
Owner:PRECEDE BIOSCIENCES INC +1

Linear nucleic acid templates for high-efficient cell-free protein expression

96 New PCT-Patent Application based on EP 24 186 635.9 Insempra GmbH Vossius Ref.: AG4141 PCT S3 Abstract The present invention relates to a linear double-stranded deoxyribonucleic acid (dsDNA) molecule comprising one or more Tus protein (Tus) binding site(s) at the 5'-terminus, one or more Lac repressor protein (LacI) binding site(s) at the 3'-terminus, and a segment comprising a DNA sequence of interest (DOI) between said Tus binding site(s) and said LacI binding site(s). The present invention further relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from the linear dsDNA molecule of the invention, and to an expression DNA cassette comprising a promoter, an RBS, a GOI encoding a POI, and one or more LacI binding site(s), wherein said expression cassette does not comprise a terminator sequence between the 3´ end of said GOI and said one or more LacI binding site(s). The present invention also relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from said expression cassette. The present invention further relates to method of protecting a linear deoxyribonucleic acid (DNA) molecule from exonuclease degradation by adding one or more Tus binding site(s) at the first terminus of the DNA molecule and adding one or more LacI binding site(s) at the other terminus of the DNA molecule. The present invention further relates to a method of synthesizing a protein of interest (POI) in a cell- free protein synthesis (CFPS) reaction mixture by using the (ds)DNA and / or RNA molecules of the invention, and also to a cell-free biological system or CFPS reaction mixture comprising the (ds)DNA, expression cassette and / or RNA molecules of the invention.
Owner:INSEMPRA GMBH

Systems and methods for clustering in cell-free networks

PCT designated stage expiredWO2025034493A1Network topologiesNetwork planningCell freeMessage delivery
Systems and methods for clustering in cell-free networks are described herein. A cluster of one or more base stations provides radio access network (RAN) functionality to a user equipment (UE) within the wireless communication system in a cell-free manner (e.g., without using a base-station-centric cell context, as in prior wireless communication systems). A cluster that is serving a UE comprises one or more connected base stations (cBSs) that actively serve the UE. A clustering control function (CCF) of the network establishes and maintains the cluster that is serving one or more UEs. Herein, messaging systems and messaging types used by the CCF, base station(s), and UE(s) within this cell-free context are discussed. Initial clustering methods used by a CCF to form a cluster for a UE are discussed. Further, clustering update methods used by a CCF to maintain / modify a cluster for a UE are discussed.
Owner:APPLE INC

Temperature-sensitive injectable pedunculoside hydrogel as well as preparation method and application of temperature-sensitive injectable pedunculoside hydrogel

The invention relates to the technical field of medicines, and discloses pedunculoside temperature-sensitive injectable hydrogel as well as a preparation method and application thereof. Specifically, the invention provides application of the temperature-sensitive injectable hydrogel with the pedunculoside in preparation of the medicine for treating the cardiovascular diseases, and the temperature-sensitive injectable hydrogel with the pedunculoside comprises the pedunculoside, a lactic acid-glycolic acid copolymer, polyvinyl alcohol and dipolylactic acid-glycolic acid copolymer polyethylene glycol. The microsphere-gel combined delivery preparation PE-M / Ge prepared by the preparation method disclosed by the invention is good in injectability and has a good temperature-sensitive gelling characteristic in vitro; the obvious gel property is realized, and the microspheres are uniformly distributed in the gel; the release of the drug can be effectively reduced, the release curve is closer to zero-order release, the dual controlled release system can more stably release the drug, the toxic and side effects caused by non-characteristic distribution of PE are reduced, and the bioavailability is improved. And the PE-M / Ge has no cytotoxicity to H9c2 cells and HUVECs cells, so that a foundation is laid for in-vivo pharmacodynamic experiments of rats.
Owner:LISHUI UNIV

Apparatuses, devices and methods for facilitating energy savings in a wireless network system

Aspects of the present disclosure provide methods, apparatuses, devices and systems for facilitating energy savings in a wireless network system, such as a user equipment (UE) centric –cell free (UC-CF) wireless system. By virtue of aspects of the present disclosure, network devices may be dynamically turned on / off so that energy usage may be effectively reduced at both the network side and the UE side without sacrificing performance. A network device may transmit information of a first set of cooperation network devices to the UE. The network device may determine at least one target network side device which belongs to the first set of cooperation network side devices. The network device may transmit, to the UE, an indication of the at least one target network device via lower layer signaling. The UE may establish a first connection with the at least one target network device.
Owner:HUAWEI TECH CO LTD

Microbial and human cell-free DNA biomarkers for diagnosing and assessing the severity of inflammatory bowel disease

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.
Owner:KARIUS INC

Cell-free protein synthesis system based on ribozyme regulation and application thereof

The invention discloses a cell-free protein synthesis system based on ribozyme regulation and application thereof, the cell-free protein synthesis system comprises an RNA report chain and a ribozyme inhibition chain, and when a pathogen target does not exist, the ribozyme inhibition chain can be specifically combined with a ribozyme sequence on the RNA report chain and inhibit the cleavage activity of ribozyme. When a pathogen target exists, the ribozyme inhibition chain is specifically combined with the pathogen target, the cleavage activity of ribozyme and the translation activity of the RNA report chain are activated, and report protein is expressed, so that rapid field detection of pathogens is realized, and detection of different pathogens can be realized by changing the sequence of the inhibition chain. And the cell-free protein synthesis system is more convenient to detect various high-pathogenicity pathogens.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV